Connect Portal

  • Clinical Testing
    • OmniSeq INSIGHT
    • Order Test
    • Specimen Requirements
  • BioPharma Services
  • Publications
  • Patient Support
  • About
    • About
    • Leadership
    • News
    • Careers
    • Forms
    • Contact

A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors

by Christina Black | Dec 3, 2021

Prevalence of secondary immunotherapeutic targets in the absence of established immune biomarkers in solid tumors

by Christina Black | Nov 10, 2021

Novel immunotherapeutic targets in cancer of unknown primary (CUP)

by Christina Black | Nov 10, 2021

Diverse RNA expression patterns of T cell priming markers in various solid tumors and their clinical implication

by Christina Black | Sep 17, 2021

Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions

by Christina Black | May 27, 2021

« Older Entries

Follow Us on Twitter

OmniSeq Follow

Finding the right drug or the right trial...for every #cancer patient. #immunotherapy Pronounced OmniSeek

Avatar
Avatar OmniSeq @omniseq ·
3 Jun

LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
https://tinyurl.com/59xf82c6
@OmniSeq
@Labcorp
#oncology
#precisionmedicine

Reply on Twitter 1532751537994342401 Retweet on Twitter 1532751537994342401 Like on Twitter 1532751537994342401 5 Twitter 1532751537994342401
Avatar OmniSeq @omniseq ·
27 May

June 3-7 | Chicago, I Join us @ASCO 2022. LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
#2561-Developmental Therapeutics—Immunotherapy
Sunday, June 5, 8-11:00 AM CDT

Reply on Twitter 1530217104867196928 Retweet on Twitter 1530217104867196928 Like on Twitter 1530217104867196928 3 Twitter 1530217104867196928
Avatar OmniSeq @omniseq ·
27 May

June 3-7 | Chicago, IL Join us at the @ASCO 2022. Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance.
#376244-Developmental Therapeutics—Immunotherapy Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT

Reply on Twitter 1530216482998734850 Retweet on Twitter 1530216482998734850 Like on Twitter 1530216482998734850 3 Twitter 1530216482998734850
Avatar OmniSeq @omniseq ·
27 May

June 3-7 | Chicago, IL Join us at the 2022 ASCO Annual Meeting.
Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD-L1 IHC.
#2623 -Developmental Therapeutics—Immunotherapy
Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT

Reply on Twitter 1530215721862680578 Retweet on Twitter 1530215721862680578 Like on Twitter 1530215721862680578 1 Twitter 1530215721862680578
Avatar OmniSeq @omniseq ·
5 May

Last year, the Buffalo-based cancer diagnostics firm @OmniSeq quietly was acquired by one of the world's largest life science companies, @Labcorp . Developing molecular diagnostic tests for cancer patients, OmniSeq is looking to scale its operations.
https://tinyurl.com/muxryphz

Reply on Twitter 1522266608911142917 Retweet on Twitter 1522266608911142917 Like on Twitter 1522266608911142917 6 Twitter 1522266608911142917
Load More...

  • Facebook
  • Twitter
©2022 OmniSeq Corporation | Privacy Practices and Terms of Use. Regulatory   .